

LA JOLLA PHARMACEUTICAL CO

Form 3

January 11, 2016

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â CARVER JENNIFER

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

01/01/2016

3. Issuer Name **and** Ticker or Trading Symbol

LA JOLLA PHARMACEUTICAL CO [LJPC]

4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

Sr. Vice President, Operations

C/O LA JOLLA  
PHARMACEUTICAL  
COMPANY,,Â 10182 TELESIS  
COURT, 6TH FLOOR

(Street)

SAN DIEGO,Â CAÂ 92121

(City)

(State)

(Zip)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
☒ Form filed by One Reporting  
Person  
☐ Form filed by More than One  
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

2,500

D

Â

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)3. Title and Amount of  
Securities Underlying  
Derivative Security4. Conversion  
or Exercise5. Ownership  
Form of6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

# Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (1)	02/07/2024	Common Stock	18,000	\$ 7.26	D	Â
Stock Option (Right to Buy)	Â (2)	05/22/2024	Common Stock	10,000	\$ 7.69	D	Â
Stock Option (Right to Buy)	Â (3)	01/09/2025	Common Stock	12,000	\$ 19.8	D	Â
Stock Option (Right to Buy)	Â (4)	02/23/2025	Common Stock	23,500	\$ 19.69	D	Â
Stock Option (Right to Buy)	Â (5)	08/31/2025	Common Stock	20,000	\$ 35.58	D	Â
Stock Option (Right to Buy)	Â (6)	12/21/2025	Common Stock	51,000	\$ 28.24	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
CARVER JENNIFER C/O LA JOLLA PHARMACEUTICAL COMPANY, 10182 TELESIS COURT, 6TH FLOOR SAN DIEGO, CA 92121	Â	Â	Â Sr. Vice President, Operations	Â

## Signatures

/s/ Ryan Murr, as attorney-in-fact for Jennifer A. Carver

01/11/2016

\_\_Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on February 7, 2015, with the remaining 13,500 shares vesting quarterly thereafter over the next three years.
- (2) This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on May 22, 2015, with the remaining 7,500 shares vesting quarterly thereafter over the next three years.
- (3) This option represents a right to purchase a total of 12,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on November 20, 2015, with the remaining 9,000 shares vesting monthly thereafter over the next three years.
- (4) This option represents a right to purchase a total of 23,500 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on February 23, 2016, with the remaining 17,625 shares vesting monthly thereafter over the next three years.
- (5) Option vests and becomes exercisable upon the achievement of certain performance-related goals in 2016. The timing for the achievement of such goals determines the number of shares underlying the award.

## Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 3

- (6) This option represents a right to purchase a total of 51,000 shares of the Issuer's Common Stock one quarter of which shall be fully vested and exercisable on December 21, 2016, with the remaining 38,250 shares vesting quarterly thereafter over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.